Publications 2002
  1. Fei B-Y, Deng C-S, Xia B, Zhu Y-Q, Crusius JBA, and Peña AS.
    Polymorphisms at the TNF Locus in Chinese Han Population.

    Human Immunology 2002;63:71–75.
  2. Murillo L, Crusius JBA, van Bodegraven AA, Alizadeh BZ and Peña AS.
    CARD15 gene and the classification of Crohn's disease.
    Immunogenetics 2002; 54:59-61.
  3. Seegers D, Bouma G, and Peña AS.
    A critical approach to new forms of treatment of Crohn's disease and ulcerative colitis.

    Aliment Pharmacol Ther. 2002 Jul;16 Suppl 4:53-58.
  4. Lachmeijer AM, Nosti-Escanilla MP, Bastiaans EJ, Pals G, Sandkuijl LA, Kostense PJ, Aarnoudse JG, Crusius JBA, Peña AS, Dekker GA, Arngrímsson R, ten Kate L P.
    Linkage and association studies of IL1B and IL1RN gene polymorphisms in preeclampsia.

    Hypertens Pregnancy. 2002;21:23-38.
     
  5. Vader W, Kooy Y, van Veelen P, de Ru A, Harris D, Benckhuijsen W, Peña S, Mearin L, Drijfhout JW, Koning F.
    The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides.
    Gastroenterology 2002; 122: 1929-1737.
    This article is referenced by:
    Susi Martucci and Gino Roberto Corazza (editorial) Spreading and focusing of gluten epitopes in celiac disease
    Gastroenterology June 2002;122;2072-2074
  6. Wu K , Crusius JBA, Shivananda S , Fan D, Peña AS.
    The Immunogenetics and Pathogenesis of Gastric Cancer. Highlights of the First Sino-European Workshop on the Immunogenetics and Pathogenesis of Gastric Cancer.

    Drugs of Today 2002, 38: 391-417.
  7. van Veen T, Kalkers NF, Crusius JBA, van Winsen L, Barkhof F, Jongen PJ, Peña AS, Polman CH, Uitdehaag BMJ.
    The FAS-670 polymorphism influences susceptibility to multiple sclerosis.
    J Neuroimmunol 2002; 128:95-100.
     
  8. Peña AS, Peñate M.
    Susceptibilidad genética y regulación de la inflamación en la enfermedad de Crohn. Relación con el sistema inmune innato.
    REV ESP ENFERM DIG (Madrid) 2002;94 (6):351-355.
     

    Peña AS, Peñate M.
    Genetic susceptibility and regulation of inflammation in Crohn's disease. Relationship with the innate immune system.
    REV ESP ENFERM DIG (Madrid) 2002;94 (6):356-360

  9. Bouma G, Kaushiva A, and Strober W.
    Experimental Murine Colitis Is Regulated By Two Genetic Loci, Including One on Chromosome 11 That Regulates IL-12 Responses.
    Gastroenterology 2002;123(2): 554-565.
  10. Seegers D, Zwiers A, Strober W, Peña AS, Bouma G.

    A TaqI polymorphism in the 3' UTR of the IL-12 p40 gene correlates with increased IL-12 secretion.

    Genes and Immunity 2002;3(7):419-423.
  11. van der Paardt M, Crusius JBA, García-González MA, Baudoin P, Kostense PJ, Dijkmans BAC, Peña AS, van der Horst-Bruinsma IE.
    Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis.
    Rheumatology (Oxford) 2002;41:1419-1423.
  12. Xia B, Crusius JBA, Wu J, Zwiers A, van Bodegraven AA, Peña AS.
    CTLA4
    Gene Polymorphisms in Dutch and Chinese Patients with Inflammatory Bowel Disease.

    Scand J Gastroenterology 2002;37:1296-1300.
  13. Morré SA, Murillo LS, Spaargaren J, Fennema HSA, Peña AS

    Role of the Toll-Like Receptor 4 Asp299Gly polymorphism in susceptibility to Candida albicans infection.
    J Infect Dis 2002 (letter);186:1377-9.

  14. Laine ML, Farré MA, García-González MA, van Dijk LJ, Ham AJ, Winkel EG, Crusius JBA, Vandenbroucke JP, van Winkelhoff AJ. Peña, A. S.

    Risicofactoren voor adulte parodontitis: polymorfismen in de interleukine-1 genfamilie.
    Ned Tijdschr Tandheelkd 2002;109:303-306.
     

  15. Ricart E, Bouma G, Peña AS.
    The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases.
    Drugs Today (Barc) 2002; 38: 725-744.
    ABSTRACT
     
  16. Morré SA, van den Brule AJ, Rozendaal L, Boeke AJP, Voorhorst FJ, de Blok S, Meijer CJLM.
    The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up.
    Int J STD & AIDS 2002;13 (Suppl. 2):12-18.
  17. van den Brule AJC, Munk C, Winther JF, Krüger Kjaer S, Jørgensen HO, Meijer CJLM, Morré SA.
    Prevalence and persistence of asymptomatic Chlamydia trachomatis infections in urine specimens from Danish male military recruits.
    Int J STD & AIDS 2002;13 (Suppl. 2):19-22.
  18. Postma MJ, Welte R, Morré SA.
    Cost-effectiveness of widespread screening for Chlamydia trachomatis.
    Expert Opin Pharmacother. 2002;3:1443-50.
  19. van Valkengoed IGM, Morré SA, van den Brule AJC, Meijer CJLM, Bouter LM, van Eijk JT, Boeke AJP.
    Partner notification among asymptomatic Chlamydia trachomatis cases, by means of mailed specimens.
    Br J Gen Pract. 2002;52:652-4.
  20. van Valkengoed IGM, Morré SA, van den Brule AJC, Meijer CJLM, Bouter LM, van Eijk JT, Boeke AJP.
    Follow-up, treatment, and reinfection rates among asymptomatic Chlamydia trachomatis cases in general practice.

    Br J Gen Pract. 2002;52:623-7.
  21. Morré SA, Welte R, Postma MJ.
    Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing.
    Sex Transm Infect. 2002;78:74-5.
  22. Postma MJ, Welte R, van den Hoek JA, Morré SA.
    Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches.
    Sex Transm Infect. 2002;78:73-4.
  23. Morré SA, Munk C, Persson K, Kruger-Kjaer S, van Dijk R, Meijer CJLM, van den Brule AJC.
    Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies.
    J Clin Microbiol. 2002;40:584-7.
  24. van Valkengoed IGM, Morré SA, Meijer CJLM, van den Brule AJC, Boeke AJP.
    Do questions on sexual behaviour and the method of sample collection affect participation in a screening programme for asymptomatic Chlamydia trachomatis infections in primary care?
    Int J STD AIDS. 2002;13:36-8.